David Magalashvili

1.7k total citations · 1 hit paper
48 papers, 1.1k citations indexed

About

David Magalashvili is a scholar working on Pathology and Forensic Medicine, Neurology and Oncology. According to data from OpenAlex, David Magalashvili has authored 48 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Pathology and Forensic Medicine, 14 papers in Neurology and 13 papers in Oncology. Recurrent topics in David Magalashvili's work include Multiple Sclerosis Research Studies (36 papers), Peripheral Neuropathies and Disorders (12 papers) and SARS-CoV-2 and COVID-19 Research (9 papers). David Magalashvili is often cited by papers focused on Multiple Sclerosis Research Studies (36 papers), Peripheral Neuropathies and Disorders (12 papers) and SARS-CoV-2 and COVID-19 Research (9 papers). David Magalashvili collaborates with scholars based in Israel, Georgia and Switzerland. David Magalashvili's co-authors include Anat Achiron, Mark Dolev, Michael Gurevich, Shay Menascu, Sapir Dreyer-Alster, Shlomo Flechter, Yael Stern, Rina Falb, Gil Harari and Mathilda Mandel and has published in prestigious journals such as PLoS ONE, Neurology and Scientific Reports.

In The Last Decade

David Magalashvili

46 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

2021 235 citations Anat Achiron, Mathilda Mandel et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Magalashvili Israel	16	810	441	385	222	150	48	1.1k
Mark Dolev Israel	18	1.0k 1.3×	441 1.0×	441 1.1×	257 1.2×	141 0.9×	50	1.4k
Robert Hoepner Switzerland	19	543 0.7×	169 0.4×	324 0.8×	169 0.8×	292 1.9×	96	1.1k
Alexander Winkelmann Germany	15	585 0.7×	193 0.4×	239 0.6×	164 0.7×	156 1.0×	43	828
Shlomo Flechter Israel	15	606 0.7×	433 1.0×	320 0.8×	294 1.3×	105 0.7×	39	1.0k
Romain Deschamps France	19	795 1.0×	274 0.6×	651 1.7×	110 0.5×	153 1.0×	76	1.3k
Yael Stern Israel	11	526 0.6×	170 0.4×	258 0.7×	132 0.6×	57 0.4×	15	679
Amir‐Hadi Maghzi United States	19	569 0.7×	115 0.3×	291 0.8×	131 0.6×	65 0.4×	44	960
Élisabeth Maillart France	17	693 0.9×	86 0.2×	439 1.1×	139 0.6×	106 0.7×	100	1.0k
Tetsuya Akaishi Japan	21	1.1k 1.3×	170 0.4×	1.1k 2.8×	144 0.6×	129 0.9×	136	1.8k
Gülay Alper United States	19	677 0.8×	170 0.4×	729 1.9×	86 0.4×	61 0.4×	33	1.4k

Countries citing papers authored by David Magalashvili

Since Specialization

Citations

This map shows the geographic impact of David Magalashvili's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Magalashvili with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Magalashvili more than expected).

Fields of papers citing papers by David Magalashvili

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Magalashvili. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Magalashvili. The network helps show where David Magalashvili may publish in the future.

Co-authorship network of co-authors of David Magalashvili

This figure shows the co-authorship network connecting the top 25 collaborators of David Magalashvili. A scholar is included among the top collaborators of David Magalashvili based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Magalashvili. David Magalashvili is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Regev, Keren, et al.. (2026). Heterogeneous response to efgartigimod in real-world experience with myasthenia gravis: Predictors and treatment strategies. Neurotherapeutics. 23(1). e00837–e00837.

Achiron, Anat, et al.. (2025). Positive impact of cladribine tablets on reducing brain atrophy in patients with relapsing-remitting multiple sclerosis: A longitudinal study. Multiple Sclerosis Journal. 31(6). 689–695. 1 indexed citations

Gurevich, Michael, Rina Zilkha‐Falb, J L Sherman, et al.. (2024). Machine learning–based prediction of disease progression in primary progressive multiple sclerosis. Brain Communications. 7(1). fcae427–fcae427. 1 indexed citations

Menascu, Shay, Sapir Dreyer-Alster, David Magalashvili, et al.. (2023). Intravenous immunoglobulin treatment during pregnancy and the post-partum period in women with multiple sclerosis: A prospective analysis. Multiple Sclerosis Journal - Experimental Translational and Clinical. 9(1). 3090514327–3090514327. 4 indexed citations

Petrou, Panayiota, Anat Achiron, David Magalashvili, et al.. (2023). Practical recommendations on treatment of multiple sclerosis with Cladribine: an Israeli Experts Group Viewpoint. Journal of Neurology. 270(11). 5188–5195. 3 indexed citations

Achiron, Anat, Mathilda Mandel, Sapir Dreyer-Alster, et al.. (2023). In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab. Multiple Sclerosis and Related Disorders. 72. 104616–104616. 3 indexed citations

Magalashvili, David, Sapir Dreyer-Alster, Chen Hoffmann, et al.. (2023). Radiological Disease Activity in Secondary Progressive Multiple Sclerosis. European Neurology. 86(2). 116–120. 2 indexed citations

Dreyer-Alster, Sapir, Shay Menascu, Mark Dolev, et al.. (2022). Longitudinal relationships between disability and gait characteristics in people with MS. Scientific Reports. 12(1). 3653–3653. 6 indexed citations

Dreyer-Alster, Sapir, Shay Menascu, Mathilda Mandel, et al.. (2022). COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose. Journal of the Neurological Sciences. 434. 120155–120155. 40 indexed citations

10.

Achiron, Anat, Mathilda Mandel, Michael Gurevich, et al.. (2022). Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod. Journal of Neurology. 269(5). 2286–2292. 27 indexed citations

11.

Magalashvili, David, Mathilda Mandel, Sapir Dreyer-Alster, et al.. (2022). Cladribine treatment for highly active multiple sclerosis: Real-world clinical outcomes for years 3 and 4. Journal of Neuroimmunology. 372. 577966–577966. 15 indexed citations

12.

Menascu, Shay, Aviva Fattal‐Valevski, Adi Vaknin‐Dembinsky, et al.. (2021). Effect of natalizumab treatment on the rate of No Evidence of Disease Activity in young adults with multiple sclerosis in relation to pubertal stage. Journal of the Neurological Sciences. 432. 120074–120074. 6 indexed citations

13.

Achiron, Anat, Alon Ben‐David, Michael Gurevich, et al.. (2020). Parity and disability progression in relapsing–remitting multiple sclerosis. Journal of Neurology. 267(12). 3753–3762. 12 indexed citations

14.

Mizandari, Malkhaz, et al.. (2016). ULTRASOUND AND CT GUIDED THORACIC BIOPSY APPROACHES - EFFECTIVENESS AND COMPLICATIONS.. PubMed. 32–9. 4 indexed citations

15.

Kalron, Alon, David Magalashvili, Mark Dolev, et al.. (2015). A personalized, intense physical rehabilitation program improves walking in people with multiple sclerosis presenting with different levels of disability: a retrospective cohort. BMC Neurology. 15(1). 21–21. 27 indexed citations

16.

Barak, Yoram, et al.. (2014). Effect of Alfacalcidol on Fatigue in MS Patients: A Randomized, Double-Blind Study (S23.004). Neurology. 82(10_supplement). 3 indexed citations

17.

Achiron, Anat, Joab Chapman, David Magalashvili, et al.. (2013). Modeling of Cognitive Impairment by Disease Duration in Multiple Sclerosis: A Cross-Sectional Study. PLoS ONE. 8(8). e71058–e71058. 119 indexed citations

18.

Achiron, Anat, Anna Feldman, David Magalashvili, Mark Dolev, & Michael Gurevich. (2012). Suppressed RNA-Polymerase 1 Pathway Is Associated with Benign Multiple Sclerosis. PLoS ONE. 7(10). e46871–e46871. 20 indexed citations

19.

Achiron, Anat, Itamar Grotto, Ran D. Balicer, et al.. (2010). Microarray analysis identifies altered regulation of nuclear receptor family members in the pre-disease state of multiple sclerosis. Neurobiology of Disease. 38(2). 201–209. 66 indexed citations

20.

Achiron, Anat, et al.. (2004). Understanding Autoimmune Mechanisms in Multiple Sclerosis Using Gene Expression Microarrays: Treatment Effect and Cytokine‐related Pathways. Journal of Immunology Research. 11(3-4). 299–305. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact